EP1000017A4 - Antagonistes du recepteur il-8 - Google Patents

Antagonistes du recepteur il-8

Info

Publication number
EP1000017A4
EP1000017A4 EP98938138A EP98938138A EP1000017A4 EP 1000017 A4 EP1000017 A4 EP 1000017A4 EP 98938138 A EP98938138 A EP 98938138A EP 98938138 A EP98938138 A EP 98938138A EP 1000017 A4 EP1000017 A4 EP 1000017A4
Authority
EP
European Patent Office
Prior art keywords
receptor antagonists
antagonists
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98938138A
Other languages
German (de)
English (en)
Other versions
EP1000017A1 (fr
Inventor
Katherine L Widdowson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1000017A1 publication Critical patent/EP1000017A1/fr
Publication of EP1000017A4 publication Critical patent/EP1000017A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP98938138A 1997-07-29 1998-07-29 Antagonistes du recepteur il-8 Withdrawn EP1000017A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5400197P 1997-07-29 1997-07-29
US54001P 1997-07-29
PCT/US1998/015830 WO1999006354A1 (fr) 1997-07-29 1998-07-29 Antagonistes du recepteur il-8

Publications (2)

Publication Number Publication Date
EP1000017A1 EP1000017A1 (fr) 2000-05-17
EP1000017A4 true EP1000017A4 (fr) 2000-10-18

Family

ID=21988053

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98938138A Withdrawn EP1000017A4 (fr) 1997-07-29 1998-07-29 Antagonistes du recepteur il-8

Country Status (5)

Country Link
EP (1) EP1000017A4 (fr)
JP (1) JP2001512096A (fr)
AU (1) AU8673198A (fr)
CA (1) CA2294064A1 (fr)
WO (1) WO1999006354A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2366897C (fr) 1999-04-06 2009-11-17 Andrew B. Onderdonk Compositions immunomodulatrices et procedes d'utilisations connexe
UY26206A1 (es) * 1999-06-16 2000-12-29 Smithkline Beecham Plc Antagonistas del receptor de il-8.
FR2801585B1 (fr) 1999-11-25 2002-02-15 Fournier Ind & Sante Nouveaux antagonistes des recepteurs de l'ii-8
DE10109204A1 (de) * 2001-02-26 2002-09-19 4Sc Ag Verbindungen zur Behandlung von Protozoen-Erkrankungen
EP1395548A1 (fr) 2001-02-26 2004-03-10 4Sc Ag Derives de diphenyluree, de diamide d'acide diphenyloxalique et de diamide d'acide diphenylsulfurique et leur utilisation comme medicaments
TW200418812A (en) 2002-10-29 2004-10-01 Smithkline Beecham Corp IL-8 receptor antagonists
US7186725B2 (en) 2003-01-03 2007-03-06 Genzyme Corporation Anti-inflammatory compositions and methods
DE602004000260T2 (de) 2003-07-22 2006-08-24 Arena Pharmaceuticals, Inc., San Diego Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
ATE548353T1 (de) 2004-03-23 2012-03-15 Arena Pharm Inc Verfahren zur herstellung von substituierte n- aryl-n'-ä3-(1h-pyrazol-5-yl)phenylü-harnstoffe and intermediate davon.
SA05260357B1 (ar) 2004-11-19 2008-09-08 ارينا فارماسيتو تيكالز ، أنك مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به
PL2009992T3 (pl) 2006-04-21 2012-11-30 Glaxosmithkline Llc Antagoniści receptora IL-8
US8097626B2 (en) 2006-04-21 2012-01-17 Glaxosmithkline Llc IL-8 receptor antagonists
CA2646076C (fr) 2006-05-18 2015-06-30 Arena Pharmaceuticals, Inc. Ethers, amines secondaires et leurs derives utilises en tant que modulateurs des recepteurs 5-ht2a de la serotonine et utiles pour traiter les troubles lies a ces recepteurs
JP5406018B2 (ja) 2006-05-18 2014-02-05 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ｈｔ２ａセロトニンレセプターに関連する障害の処置に有用な５−ｈｔ２ａセロトニンレセプターのモジュレーターとしての１級アミン、およびその誘導体
SG171681A1 (en) 2006-05-18 2011-06-29 Arena Pharm Inc Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
JP5393677B2 (ja) 2007-08-15 2014-01-22 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ＨＴ２Ａセロトニン受容体に関連した障害の治療のための５−ＨＴ２Ａセロトニン受容体のモジュレーターとしてのイミダゾ［１，２−ａ］ピリジン誘導体
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
CA2741731A1 (fr) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Compositions de modulateurs du recepteur de la serotonine 5-ht2a utilespour le traitement des troubles associesaudit recepteur
WO2011075596A1 (fr) 2009-12-18 2011-06-23 Arena Pharmaceuticals, Inc. Formes cristallines de certains dérivés de 3-phényl-pyrazole, modulatrices du récepteur 5-ht2a de la sérotonine, utiles pour le traitement de troubles y étant associés
US10022355B2 (en) 2015-06-12 2018-07-17 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder
BR112018000728A2 (pt) 2015-07-15 2018-09-04 Axovant Sciences Gmbh resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2245927A1 (fr) * 1995-02-17 1997-08-21 Daniel Frank Veber Antagonistes de recepteurs de l'interleukine-8
WO1997049286A1 (fr) * 1996-06-27 1997-12-31 Smithkline Beecham Corporation Antagonistes des recepteurs d'il-8

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780483A (en) * 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2245927A1 (fr) * 1995-02-17 1997-08-21 Daniel Frank Veber Antagonistes de recepteurs de l'interleukine-8
WO1997049286A1 (fr) * 1996-06-27 1997-12-31 Smithkline Beecham Corporation Antagonistes des recepteurs d'il-8

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9906354A1 *

Also Published As

Publication number Publication date
WO1999006354A1 (fr) 1999-02-11
CA2294064A1 (fr) 1999-02-11
EP1000017A1 (fr) 2000-05-17
AU8673198A (en) 1999-02-22
JP2001512096A (ja) 2001-08-21

Similar Documents

Publication Publication Date Title
IL134855A0 (en) Il-8 receptor antagonists
IL131004A0 (en) Il-8 receptor antagonists
IL127666A0 (en) IL-8 receptor antagonists
IL127667A0 (en) IL-8 receptor antagonists
EP0932405A4 (fr) Antagonistes des recepteurs d'il-8
IL128501A0 (en) IL-8 receptor antagonists
EP0907362A4 (fr) Antagonistes des recepteurs d'il-8
EP1000017A4 (fr) Antagonistes du recepteur il-8
EP1019035A4 (fr) Antagonistes du recepteur d'il-8
EP0920417A4 (fr) Antagonistes du recepteur de l'il-8
IL131005A0 (en) Il-8 receptor antagonists
ZA988101B (en) IL-8 receptor antagonists
EP0971908A4 (fr) Antagoniste de recepteurs d'il-8
EP0923373A4 (fr) Antagonistes du recepteur d'il-8
EP0957907A4 (fr) Antagonistes du recepteur de l'il-8
EP0939634A4 (fr) Antagonistes du recepteur il-8
EP0934066A4 (fr) Antagonistes du recepteur de l'interleukine-8 (il-8)
EP1047424A4 (fr) Antagonistes des recepteurs il-8
EP1039903A4 (fr) Antagonistes des recepteurs de l'interleukine-8
EP0920253A4 (fr) Antagonistes du recepteur il-8
EP0948330A4 (fr) Antagonistes du recepteur d'il-8
IL140983A0 (en) Il-8 receptor antagonists
ZA98519B (en) Il-8 receptor antagonists
HUP9904303A3 (en) Il-8 receptor antagonists
HUP9903949A3 (en) Il-8 receptor antagonists

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000113

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: SI PAYMENT 20000113

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07C 275/42 A, 7A 61K 31/17 B, 7C 07C 241/00 -

A4 Supplementary search report drawn up and despatched

Effective date: 20000830

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20001120

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1028232

Country of ref document: HK